Jazz Pharmaceuticals Scheduled to Report Q3 2026 Earnings
Jazz Pharmaceuticals (JAZZ) is set to release its third-quarter 2026 financial results on Monday, November 2, following the close of the market. The report comes at a time when investors are closely monitoring year-over-year shifts in profitability and top-line growth. Market consensus estimates project a revenue of $1.21 billion, representing a 7.1% increase compared to the previous year. However, earnings per share (EPS) are expected to be -$2.21, marking a significant year-over-year decline of approximately 127.2%.
Tickers: $JAZZ